Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Refining retinoids with heteroatoms.

D M Benbrook1

  • 1Department of Obstetrics and Gynecology, The University of Oklahoma Health Science Center, P.O. Box 26901, Room WP2470, Oklahoma City, OK 73190, USA. Doris-Benbrook@ouhsc.edu

Mini Reviews in Medicinal Chemistry
|October 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ki-67 Expression in a Cervical Cancer Organotypic Model Correlates with Growth and EGF-R Expression.

Journal of lower genital tract disease·2015
Same author

The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.

Gynecologic oncology·2013
Same author

Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis.

Experimental oncology·2012
Same author

Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.

Oncogene·2011
Same author

Nonphotochemical hole-burning study of selectively stained normal and cancerous human ovarian tissues.

The journal of physical chemistry. B·2006
Same author

Effect of all-trans retinoic acid on tissue dynamics of choriocarcinoma cell lines: an organotypic model.

Journal of clinical pathology·2006
Same journal

PROTAC-Mediated Targeting of PARP via CRBN: Mechanistic Insights, Resistance Challenges, and Therapeutic Advancements.

Mini reviews in medicinal chemistry·2026
Same journal

Recent Advancements in the Development of Heterocyclic Scaffolds as Potential Anti-cancer Agents Targeting EGFR and VEGFR-2.

Mini reviews in medicinal chemistry·2026
Same journal

Exploring the Anticancer Potential of Synthetic β-Carboline Derivatives: A Comprehensive Systematic Review.

Mini reviews in medicinal chemistry·2026
Same journal

KIF20A in Human Malignancies: Oncogenic Mechanisms and Therapeutic Targeting Strategies.

Mini reviews in medicinal chemistry·2026
Same journal

Phytocompound-loaded Biomaterial-based Scaffolds: Emerging Strategies for Wound Healing Applications.

Mini reviews in medicinal chemistry·2026
Same journal

Bioprospecting of Natural Products as Sources of New Multitarget Therapies.

Mini reviews in medicinal chemistry·2026
See all related articles

Synthetic retinoids offer pharmaceutical applications for diseases like cancer. Modifying structures to reduce toxicity while maintaining efficacy, such as with heteroarotinoids like Tazarotene, improved cancer treatment options.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Retinoids, derived from retinoic acid, are explored for pharmaceutical applications, notably in cancer treatment.
  • Conformationally restricted retinoids (arotinoids) show biological activity but are associated with heightened toxicity.
  • Structural modifications are crucial for optimizing retinoid drug profiles.

Purpose of the Study:

  • To investigate the impact of incorporating heteroatoms into arotinoid structures.
  • To assess the resulting changes in biological activity and toxicity.
  • To evaluate the therapeutic potential of novel heteroarotinoid compounds.

Main Methods:

  • Synthesis of conformationally restricted retinoids with heteroatom incorporation.
  • Biological activity assays to determine efficacy.

Related Experiment Videos

  • Toxicity assessments to evaluate safety profiles.
  • Clinical trials of lead compounds.

    • Main Results:

    • Heteroatom incorporation into arotinoid structures significantly reduced toxicity.
    • Biological activity was preserved despite toxicity reduction.
    • The heteroarotinoid Tazarotene demonstrated an improved efficacy/toxicity ratio in clinical trials.

    Conclusions:

    • Heteroarotinoids represent a promising class of compounds for cancer therapy.
    • Structural modification, specifically heteroatom inclusion, is a viable strategy to enhance the therapeutic index of retinoids.
    • Tazarotene's successful clinical trial validates the potential of heteroarotinoids in improving cancer treatment outcomes.